Compare KRO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRO | DSGN |
|---|---|---|
| Founded | 1916 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 853.8M |
| IPO Year | 2004 | 2021 |
| Metric | KRO | DSGN |
|---|---|---|
| Price | $8.18 | $12.27 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $15.25 |
| AVG Volume (30 Days) | 325.7K | ★ 598.0K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,859,400,000.00 | N/A |
| Revenue This Year | $6.75 | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $90.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $5.28 |
| 52 Week High | $9.17 | $17.25 |
| Indicator | KRO | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 36.89 |
| Support Level | $5.97 | $9.78 |
| Resistance Level | $9.03 | $13.54 |
| Average True Range (ATR) | 0.39 | 0.65 |
| MACD | -0.13 | -0.23 |
| Stochastic Oscillator | 11.11 | 3.56 |
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The maximum of revenue comes from the United States.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.